Medicare Plans, a patient support center that provides resources for better understanding Medicare, recently conducted a survey about the idea of Medicare coverage for medical cannabis treatment and products. Here are some highlights from their results.
Recently, Medicare Plans, a patient support center that helps provide resources for understanding Medicare, conducted a survey of current Medicare recipients on their opinions of Medicare coverage for medical cannabis treatment and products (1). The survey was conducted online with 1250 Americans ages 65 and over surveyed. It covered topics such as past and current cannabis use, political affiliations, and how much patients spent on cannabis products per month. Medicare Plans released their survey results this month.
Some of the most prominent findings, according to Medicare Plans, included:
Medicare Plans pointed out that currently the use of medical cannabis is legal in 37 states, four territories, and the District of Columbia. However, because cannabis is both illegal at the federal level and, in most cases, not approved by the US Food and Drug Administration (FDA), health insurance does not pay for it. Medicare Plans also noted that with the recent passing of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act in the House of Representatives, the question of whether insurance should cover medical cannabis may soon need to be addressed.
To see the survey results in detail, please visit: https://www.medicareplans.com/1-in-5-medicare-recipients-use-medical-marijuana/
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.